These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 12821303)

  • 1. Chemistry challenges in lead optimization: silicon isosteres in drug discovery.
    Showell GA; Mills JS
    Drug Discov Today; 2003 Jun; 8(12):551-6. PubMed ID: 12821303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in the medicinal chemistry of silicon: C/Si exchange and beyond.
    Fujii S; Hashimoto Y
    Future Med Chem; 2017 Apr; 9(5):485-505. PubMed ID: 28362125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of lead discovery strategies on the properties of drug candidates.
    Keserü GM; Makara GM
    Nat Rev Drug Discov; 2009 Mar; 8(3):203-12. PubMed ID: 19247303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases.
    Ghose AK; Viswanadhan VN; Wendoloski JJ
    J Comb Chem; 1999 Jan; 1(1):55-68. PubMed ID: 10746014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synthesis of biologically active organosilicon small molecules.
    Franz AK
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):654-71. PubMed ID: 17987519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead-oriented synthesis: a new opportunity for synthetic chemistry.
    Nadin A; Hattotuwagama C; Churcher I
    Angew Chem Int Ed Engl; 2012 Jan; 51(5):1114-22. PubMed ID: 22271624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lead generation--enhancing the success of drug discovery by investing in the hit to lead process.
    Alanine A; Nettekoven M; Roberts E; Thomas AW
    Comb Chem High Throughput Screen; 2003 Feb; 6(1):51-66. PubMed ID: 12570752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can silicon make an excellent drug even better? An in vitro and in vivo head-to-head comparison between loperamide and its silicon analogue sila-loperamide.
    Geyer M; Wellner E; Jurva U; Saloman S; Armstrong D; Tacke R
    ChemMedChem; 2015 May; 10(5):911-24. PubMed ID: 25801200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The graphical representation of ADME-related molecule properties for medicinal chemists.
    Ritchie TJ; Ertl P; Lewis R
    Drug Discov Today; 2011 Jan; 16(1-2):65-72. PubMed ID: 21074634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploitation of silicon medicinal chemistry in drug discovery.
    Mills JS; Showell GA
    Expert Opin Investig Drugs; 2004 Sep; 13(9):1149-57. PubMed ID: 15330746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leadlikeness and structural diversity of synthetic screening libraries.
    Verheij HJ
    Mol Divers; 2006 Aug; 10(3):377-88. PubMed ID: 17031539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organic chemistry in drug discovery.
    MacCoss M; Baillie TA
    Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compound scale-up at the discovery-development interface.
    Nikitenko AA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?
    Ivanenkov YA; Zagribelnyy BA; Aladinskiy VA
    J Med Chem; 2019 Nov; 62(22):10026-10043. PubMed ID: 31188596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural Product-Based Drug Discovery.
    Li R
    Med Res Rev; 2016 Jan; 36(1):3. PubMed ID: 26662060
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology.
    Kéri G; Székelyhidi Z; Bánhegyi P; Varga Z; Hegymegi-Barakonyi B; Szántai-Kis C; Hafenbradl D; Klebl B; Muller G; Ullrich A; Erös D; Horváth Z; Greff Z; Marosfalvi J; Pató J; Szabadkai I; Szilágyi I; Szegedi Z; Varga I; Wáczek F; Orfi L
    Assay Drug Dev Technol; 2005 Oct; 3(5):543-51. PubMed ID: 16305311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finding the sweet spot: the role of nature and nurture in medicinal chemistry.
    Hann MM; Keserü GM
    Nat Rev Drug Discov; 2012 Apr; 11(5):355-65. PubMed ID: 22543468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disila-analogues of the synthetic retinoids EC23 and TTNN: synthesis, structure and biological evaluation.
    Gluyas JB; Burschka C; Dörrich S; Vallet J; Gronemeyer H; Tacke R
    Org Biomol Chem; 2012 Sep; 10(34):6914-29. PubMed ID: 22814352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoproteomics as a basis for post-genomic drug discovery.
    Beroza P; Villar HO; Wick MM; Martin GR
    Drug Discov Today; 2002 Aug; 7(15):807-14. PubMed ID: 12546968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.